Physician profile
Kent E Ray
NPI 1598754350
$2,016.93
in general payments reported to CMS, 2019-2025
14 companies · $567 in 2025
The $567 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.46 · 2020: $306 · 2021: $245 · 2022: $225 · 2023: $284 · 2024: $361 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,219.58 | 2021-2025 | Dexcom G6 Transmitter |
| Companion Medical, INC. | $237.49 | 2020 | |
| Novo Nordisk INC | $125.04 | 2019-2024 | Wegovy |
| Lilly USA, LLC | $102.52 | 2020-2025 | Jardiance, Mounjaro |
| Cequr Corporation | $96.11 | 2024 | Cequr Simplicity |
| Medtronic, INC. | $88.36 | 2022-2025 | Minimed 780g |
| Medtronic Minimed, INC. | $26.97 | 2019-2020 | |
| Amgen INC. | $23.18 | 2025 | Repatha |
| Ascensia Diabetes Care US INC. | $21.88 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.59 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.69 | 2025 | Strensiq |
| Horizon Therapeutics Plc | $14.44 | 2020 | |
| Abbott Laboratories | $14.08 | 2020 | |
| Senseonics, Incorporated | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.